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ABSTRACT  24 
Type 1 diabetes (T1D) results from T-cell mediated autoimmune destruction of pancreatic ȕ 25 
cells. Effector T-cell responses emerge early in disease development and expand as disease 26 
progresses.  Following ȕ cell destruction, a long-lived T-cell memory is generated that represents 27 
a barrier to islet transplantation and other cellular insulin-replacement therapies. Development of 28 
effective immunotherapies that control or ablate ȕ cell destructive effector and memory T cell 29 
responses has the potential to prevent disease progression and recurrence. Targeting antigen 30 
expression to antigen-presenting cells inactivates cognate CD8
+
 effector and memory T-cell 31 
responses and has therapeutic potential. Here we investigated this in the context of insulin-32 
specific responses in the non-obese diabetic mouse where genetic immune tolerance defects 33 
could impact on therapeutic tolerance induction. Insulin-specific CD8
+
 memory T cells 34 
transferred to mice expressing proinsulin in antigen-presenting cells proliferated in response to 35 
transgenically-expressed proinsulin and the majority were rapidly deleted.  A small proportion of 36 
transferred insulin-specific Tmem remained undeleted and these were antigen-unresponsive, 37 
exhibited reduced TCR expression and H-2K
d
/insB15-23 tetramer binding and expressed co-38 
inhibitory molecules.  Expression of proinsulin in antigen-presenting cells also abolished the 39 
diabetogenic capacity of CD8
+
 effector T cells. Therefore, destructive insulin-specific CD8
+
 T 40 
cells are effectively inactivated by enforced proinsulin expression despite tolerance defects that 41 
exist in diabetes-prone NOD mice. These findings have important implications in developing 42 
immunotherapeutic approaches to T1D and other T cell-mediated autoimmune diseases.43 
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INTRODUCTION 44 
Type 1 diabetes (T1D) results from the progressive inflammatory destruction of insulin-secreting 45 
pancreatic ȕ cells.  Many immune cell types are implicated in promoting ȕ-cell destructive 46 
inflammation but T cells are critical.  In humans and mice, T cells specific for pancreatic ȕ cell 47 
antigens are recruited into effector populations early during the prodromal, pre-clinical phase of 48 
autoimmune diabetes where disease is progressing 
1
.  Responses directed at (pro)insulin epitopes 49 
are prominent early in disease and determinant spreading ultimately leads to the targeting of a 50 
wide array of ȕ-cell antigens 2, 3.  Along with this, effector T cells expand as disease progresses 4-51 
6
 and ultimately form memory populations 
6
 that persist long after ȕ-cell destruction is complete.  52 
These contribute to recurrent autoimmune rejection of replacement insulin-secreting tissues such 53 
as islet transplants 
7-9
. One of the key challenges for control of memory T cell responses and 54 
particularly those in T1D is the resistance of memory T cells to regulatory T cells (Treg), 55 
conventional immunosuppression, chemotherapeutic agents 
7, 10-14
 and some methods of 56 
tolerance induction 
15, 16
.  Understanding how to effectively control effector and memory T cell 57 
responses will provide opportunities for therapeutic interventions to interrupt disease progression 58 
in T1D by limiting epitope and determinant spreading or purging established effector and 59 
memory populations and to alleviate autoimmune resistance to cellular insulin-replacement 60 
therapies.   61 
Targeting antigen expression to antigen presenting cell (APC) populations effectively ablates 62 
antigen-specific memory and effector CD4
+
 and CD8
+
 T cell responses through deletion and 63 
induction of unresponsiveness 
17-19
.  Depending on the APC type targeted, inactivation of CD8
+
 64 
effector/memory T cells occurs slowly when antigen is expressed in DC or much more rapidly 65 
when antigen is targeted to MHC class II
+
 APC 
18
, but studies have focussed on non-autoimmune 66 
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prone strains of mice.  It remains unclear whether defects that exist in immune regulation in the 67 
NOD mouse, that replicate those in T1D-prone individuals with or at-risk of T1D 
20-23
, impact on 68 
the effectiveness of immunotherapy focussed on memory T cells.  Additionally, experimental 69 
systems employed to explore tolerance induction in T cells typically employ model antigens 70 
matched to high-affinity TCR transgenic T cells rather than physiological antigens and T cells 71 
with relevant disease-associated TCR and TCR affinities.  72 
 73 
Here we sought to gain insight into the applicability of targeted antigen expression for 74 
inactivation of memory T cell responses where a natural islet antigen was targeted and 75 
TCR/pMHC affinity reflected that occurring naturally during T1D development.  We also asked 76 
whether inactivation of memory CD8
+
 T cell responses was effective in the presence of genetic 77 
defects in immune regulation that underlie disease susceptibility in a relevant autoimmune-prone 78 
model of spontaneous diabetes.  To achieve this, we used CD8
+
 T cells expressing a 79 
physiologically-relevant intermediate affinity TCR recognizing insulin B15-23 
24
 in conjunction 80 
with mice where proinsulin is expressed in diverse APC types by an MHC class II promoter 
25
.  81 
We found in the autoimmune-prone NOD strain, the majority of memory insulin-specific CD8
+
 82 
T cells transferred to mice expressing proinsulin were deleted and the remainder rapidly 83 
inactivated. Additionally, expression of proinsulin in APC ablated the diabetogenic capacity of 84 
activated insulin-specific cytotoxic T lymphocytes (CTL).  Overall, these findings were 85 
remarkably similar to those reported in analogous studies where the model antigen ovalbumin 86 
(OVA) was used in conjunction with high-affinity TCR Tg T cells 
18
.  This indicates that, at least 87 
in the NOD mouse model, perturbations of immune regulation that underlie spontaneous diabetes 88 
susceptibility do not limit the capacity of APC-expressed antigen to inactivate memory CD8
+
 T 89 
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cell responses.  Knowledge gained here in the NOD mouse model may extend our understanding 90 
of tolerance induction and guide development of therapies to control deleterious anti-ȕ cell 91 
effector and memory T cell responses.    92 
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RESULTS 93 
In vitro generation of Tmem 94 
We employed an in-vitro differentiation procedure 
17
 where G9 T cells were activated in the 95 
presence of cognate antigen (insB15-23) and IL-2 for 3 days and then washed and recultured in IL-96 
15 to induce central memory differentiation.  We have previously validated memory T cells 97 
(herein termed Tmem) generated using this and similar procedures in tolerance and other studies 98 
17, 19, 26
 and their behaviour is similar to in-vivo derived memory cells 
17
.  During in-vitro 99 
differentiation, G9 T cells underwent blastogenesis and acquired high levels of CD44 expression 100 
during insB15-23 and IL-2 stimulation (Suppl. 1A,B). After removal of insB15-23 and IL-2, and 101 
culture in IL-15, the majority of cells reacquired high levels of CD62L expression such that 102 
approximately two-thirds expressed a CD44
hi
CD62L
hi
 Tcm phenotype (Suppl. 1B-D).  103 
Following in vitro differentiation G9 Tmem showed high levels of TCR Vȕ6 expression and H-104 
2K
d
/insB15-23 tetramer binding similar to naïve G9 T cells (Suppl. 2A,B).  105 
 106 
G9 Tmem activation by transgenically-expressed proinsulin leads to rapid deletion 107 
To determine if G9 Tmem were activated by endogenous or transgenically-expressed 108 
(pro)insulin, CFSE-labelled G9 Tmem were transferred to non-Tg and proinsulin-expressing PI-109 
Tg NOD along with B16 mice that lack the G9-recognised determinant.  Three days later, G9 110 
Tmem showed little evidence of division in B16 recipients (Fig. 1A,B).  In NOD recipients, a 111 
small, but statistically-significant proportion of G9 Tmem showed evidence of division in 112 
pancreatic LN (pLN) but not skin-draining LN (sdLN) or spleen (Fig. 1A,B). Based on the 113 
proliferation index, the extent of proliferation was low in NOD pLN and at 3 days after transfer 114 
did not differ significantly to B16 mice (Fig. 1B).  In contrast, G9 Tmem showed evidence of 115 
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several rounds of division in spleen, sdLN and pLN of PI-Tg recipients  (Fig. 1A,B).  Both the 116 
proportion of cells entering division within 3 days and the extent of division in PI-Tg recipients 117 
was reduced for G9 Tmem relative to that observed for their naïve counterparts in a similar 118 
setting (submitted).  Interestingly, reduced proliferation of Tmem has been observed in a similar 119 
settings where Tn and Tm have been compared 
18
 and is in line with other observations of 120 
reduced proliferation or expansion capacity of memory relative to naïve CD8
+
 T cells 
27, 28
.  121 
 122 
Analysis of population kinetics showed G9 Tmem became distributed throughout all lymphoid 123 
tissues examined (spl, sdLN and pLN) in non-Tg and PI-Tg recipients within 1 to 2 days of 124 
transfer (Fig. 1C).  In spleen, there was a noticeable transient accumulation of G9 Tmem 1 day 125 
after transfer but this diminished, possibly through redistribution, by 2 days after transfer.  126 
Between days 2 and 7 after transfer the population of G9 Tmem remained relatively stable in size 127 
in spleen of non-Tg NOD recipients.  However, in spleens of PI-Tg recipients, the G9 Tmem 128 
population diminished slowly such that by 7 days after transfer, the population was significantly 129 
reduced in size compared to 2 days after transfer (Fig. 1C, d2 > d7, p<0.05) and G9 Tmem were 130 
significantly less frequent in PI-Tg than in non-Tg spleen 3, 5 and 7 days after transfer (p<0.01).  131 
In sdLN and pLN of non-Tg NOD recipients, stable populations of G9 Tmem became 132 
established and these remained relatively stable in number across the analysis period.  In PI-Tg 133 
recipients, significantly fewer G9 Tmem accumulated in sdLN or pLN than in non-Tg recipients 134 
(Fig. 1C, p<0.05 or greater at all time points except d2 in pLN) and the number of G9 Tmem 135 
decreased in PI-Tg pLN over time (d1 > d3, d5, d7; p<0.01 or greater, d2 > d5, d7; p< 0.05).  136 
When accumulation of G9 Tmem was analysed as a proportion of the total CD8
+
 population 137 
(Suppl. 3), a similar pattern was observed.  Accumulation of G9 T cells was not increased in PI-138 
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Tg relative to non-Tg recipients despite the substantial proliferation indicated by CFSE dilution. 139 
Overall, far fewer G9 Tmem were recovered from PI-Tg than non-Tg recipients indicating G9 140 
Tmem were deleted when proinsulin was expressed in MHC class II
+
 APC.  This, together with 141 
the relatively low numbers of G9 recovered suggests that onset of deletion may have been very 142 
rapid.  143 
 144 
G9 TCR expression is reduced in PI-transgenic recipients  145 
Enumeration suggested that G9 Tmem were rapidly deleted in PI-Tg recipients, however, a small 146 
residual population of undeleted G9 T cells remained.  Expression of TCR Vȕ6 by G9 Tmem 147 
remained relatively unchanged after transfer to non-Tg NOD recipients (Fig. 2A,B, all n.s. 148 
except spleen d1>d7, p<0.05).  However, at each time point tested, expression of TCR Vȕ6 by 149 
G9 Tmem recovered from PI-Tg recipient spleen, sdLN and pLN was reduced compared to non-150 
Tg recipients (Fig. 2B; all p<0.01 or greater).  Interestingly, the reduction in TCR Vȕ6 151 
expression in PI-Tg recipients occurred principally within the first 3 days after transfer and 152 
remained relatively stable thereafter (Fig. 2B).   TCR down-regulation is prominent in tolerance 153 
models where antigen is expressed in a high proportion of APC 
17, 29
.  To define whether 154 
proinsulin expression in a high proportion of APC was a prerequisite for TCR down-regulation 155 
we generated mixed PI-Tg/non-Tg bone marrow (BM) chimeras where proinsulin-encoding BM 156 
was titrated to control the proportion of PI-Tg APC arising in recipients.  When G9 Tmem were 157 
transferred to chimeric recipients, TCR expression on G9 was down-regulated in recipients with 158 
greater than 20% PI-Tg engraftment and in 2 of 4 recipients where there was approximately 10% 159 
PI-Tg engraftment (Fig. 2C), indicating that proinsulin expression was required in only a minor 160 
proportion of APC to induce TCR down-regulation.    161 
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 162 
G9 tetramer binding is reduced in PI-transgenic recipients  163 
We previously showed for naïve insulin-specific CD8
+
 T cells that down-regulation of TCR after 164 
transfer to PI-Tg mice was associated with loss of H-2K
d
/insB15-23 tetramer binding (manuscript 165 
submitted).  Here, for G9 Tmem, those transferred to non-Tg recipients retained high levels of H-166 
2K
d
/insB15-23 tetramer binding (Fig. 3A-C) with more than three quarters binding H-2K
d
/insB15-167 
23 tetramer at the high levels (Fig. 3A,B).  In contrast, in PI-Tg recipients the majority of G9 168 
Tmem bound less H-2K
d
/insB15-23 tetramer (Fig 3A-C) resulting in a lower proportion binding 169 
H-2K
d
/insB15-23 tetramer at high levels compared to non-Tg recipients (Fig. 3B).  In PI-Tg 170 
recipients reduced H-2K
d
/insB15-23 tetramer binding correlated with reduced TCR expression 171 
(Fig. 3C). In conjunction with the overall reduction in G9 Tmem number (Fig. 1), G9 T cells 172 
binding high levels of H-2K
d
/insB15-23 tetramer were present only as a very low, significantly 173 
reduced, proportion of total CD8
+
 T cells in PI-Tg compared to non-Tg recipients (Fig. 3D,E).   174 
 175 
G9 Tmem are rendered unresponsive in proinsulin-expressing recipients 176 
To determine whether G9 Tmem were rendered unresponsive in PI-Tg recipients, G9 Tmem 177 
were transferred to NOD and PI-Tg recipients.  Five days later recipients were immunised or not 178 
with insB15-23/IFA/poly IC and the response of G9 Tmem analysed.  In NOD recipients, G9 179 
Tmem were readily detectable in spleens of non-Tg recipients of G9 Tmem (Fig. 4A) and robust 180 
expansion of G9 in response to immunisation was observed between immunised and 181 
unimmunised non-Tg recipients (Fig. 4A).  In contrast to non-Tg recipients, G9 Tmem were 182 
infrequent in spleens of PI-Tg recipients (Fig. 4A) and present at close to the limit of flow 183 
cytometric detection determined by analysis of untransferred controls (Fig. 4A).  No 184 
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immunisation-associated expansion of G9 T cells was evident in PI-Tg recipients (Fig. 4A).  185 
InsB15-23-restimulated ELISpot assays revealed that insB15-23-responsive, IFN-Ȗ-producing G9 186 
were readily detectable in non-Tg recipients, relative to no-transfer controls and their frequency 187 
was increased by immunisation (Fig. 4C).  Notably, insB15-23 stimulation revealed virtually no 188 
insB15-23-responsive IFN-Ȗ-producing cells in spleen cells of PI-Tg recipients whether immunised 189 
or not, indicating ablation of G9 responses.  Overall the data indicates that G9 Tmem are mostly 190 
deleted in PI-Tg recipients and any residual undeleted G9 T cells are rendered unresponsive.   191 
 192 
G9 Tmem show increased expression of ‘exhaustion’ markers 193 
Increased expression of ‘co-inhibitory’ or ‘exhaustion’ markers is associated with many settings 194 
in which T-cells are inactivated. When analysed, PD-1 (CD279) , CD160 and LAG-3 (CD223) 195 
were upregulated on a significantly greater proportion of G9 Tmem in PI-Tg compared to non-196 
Tg recipients (Fig. 5A-H) such that the proportion of PD-1
+
CD160
+
 and PD-1
+
LAG-3
+
 G9 197 
Tmem was significantly increased (Fig. 5B,C).  CD244 was largely unchanged although a small 198 
proportion (approximately 25%) of PD-1
+
 G9 Tmem in PI-Tg pLN, but not elsewhere, co-199 
expressed CD244 (not shown). These differences were observed even though G9 Tmem acquired 200 
higher levels of PD-1, CD160 and LAG-3 during in vitro differentiation.  CD5 expression by G9 201 
Tmem was increased in non-Tg pLN relative to spleen, but not in PI-Tg relative to non-Tg.   202 
APC-targeted expression of proinsulin limits G9 effector function 203 
As the data indicated transgenic expression of proinsulin terminated insulin-specific memory 204 
CD8
+
 T cell responses, we examine whether effector function could also be directly modulated. 205 
G9 T cells were cultured for 2 days to generate CTL that were transferred to PI-Tg or non-Tg 206 
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control recipients.  In non-Tg recipients, transfer of 10
7
 G9 CTL induced diabetes in 207 
approximately one-quarter of recipients (Fig. 6A) in line with the diabetogenicity of these cells 
24
 208 
and the reduced incidence that would be predicted in immune-competent recipients compared to 209 
NOD.scid mice that have been used previously for similar experiments 
24
.  In contrast, after 210 
parallel transfers to PI-Tg recipients, no mice developed diabetes over the 8-week monitoring 211 
period (Fig. 6A).  In conclusion expression of proinsulin by APC not only terminated insulin-212 
specific CD8
+
 memory T cells responses but also inhibited the diabetogenicity of insulin-specific 213 
CTL.  To further understand the mechanisms of protection we determined whether G9 CTL were 214 
deleted and TCR down-regulated in PI-Tg recipients. Three days after G9 CTL transfer, the 215 
number of G9 T cells was significantly reduced in spleens, sdLN and pLN of PI-Tg recipients 216 
compared to non-Tg controls  (Fig. 6B) indicating that deletion had indeed occurred.  Analysis 217 
of TCR Vȕ6 expression revealed that although TCR expression by G9 was reduced in PI-Tg 218 
relative to non-Tg control recipients, the degree of downregulation (Fig. 6C) was not as 219 
prominent as that observed for G9 Tmem (Fig. 2).   220 
  221 
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DISCUSSION 222 
In T1D, effector and memory T cell responses directed at pancreatic ȕ cells sustain disease 223 
progression and give rise to autoimmune memory that persists as a long-term barrier to cellular 224 
insulin replacement therapies such as islet transplantation. No immunotherapies have yet been 225 
developed for clinical application that effectively prevent T1D progression or reverse established 226 
anti-ȕ-cell memory. This reflects the unmet need to effectively terminate difficult-to-control 227 
effector and memory T-cell responses.  Here we show that enforced expression of proinsulin 228 
targeted to APC rapidly and efficiently ablates insulin-specific memory CD8
+
 T-cell responses 229 
and disables the diabetogenic capacity of insulin-specific CTL. 230 
 231 
Enforced expression of antigen is a potent means to induce T-cell tolerance which is as effective 232 
for effector and memory T cells as it is for naive T cells in non-autoimmune-prone mice 
17-19
.  In 233 
humans and NOD mice, genetically-determined defects in tolerance that contribute to the 234 
development of pathogenic anti-ȕ-cell responses are present. These defects, that include 235 
perturbations in apoptotic pathways and alterations in the makeup and function of Treg and APC 236 
that impair normal tolerance induction 
21, 30
 could negatively impact on induction of therapeutic 237 
tolerance.  Indeed, establishment of transplantation tolerance meets with particular challenges 
31-
238 
33
.  However, some forms of therapeutic manipulation for tolerance induction may overcome 239 
these effects. We have found enforced antigen expression is extremely robust and not reliant on 240 
the presence of intact immunoregulatory circuits provided by, for example, NKT cells 241 
(unpublished) or Treg 
34
 unlike some other forms of therapy 
35, 36
.  Here we found that enforced 242 
expression of proinsulin by APC effectively curtailed insulin-specific memory CD8
+
 T cell 243 
responses and restrained diabetes induction by insulin-specific CTL.  This therapeutic approach 244 
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is therefore effective in the face of genetic perturbations of tolerance and immune regulatory 245 
networks that contribute to diabetes development. While detailed mechanistic studies have not 246 
have been performed in many instances, enforced expression of ȕ-cell antigens other than 247 
proinsulin, such as IGRP and GAD, appears to effectively induce tolerance in naïve CD4
+
 and 248 
CD8
+
 T cells even though this may not influence the course of autoimmune diabetes in NOD 249 
mice 
3, 37
.  Together these studies and our findings here establish the universality of enforced 250 
antigen expression for tolerance induction across a range of ȕ-cell antigens meaning that the 251 
findings presented here for memory T cells and CTL would also extend to other ȕ-cell antigens. 252 
Whether low levels of proinsulin expression and presentation by, for instance fibroreticular or 253 
other cells, that appear to modulate the responsiveness of naïve insulin-specific CD8+ T cells 
38
 254 
can similarly influence the function of insulin-specific Tmem or CTL remains to be determined.   255 
 256 
Most insulin-specific memory CD8
+
 T cells were rapidly deleted after encountering proinsulin-257 
expressing APC and those remaining undeleted were rendered unresponsive.  The substantial 258 
TCR down-regulation we observed indicates that loss of antigen signalling likely plays a key role 259 
in maintaining unresponsiveness but is potentially reinforced by the actions of co-inhibitory 260 
molecules such as PD-1, CD160, LAG-3 and CD244 that are also upregulated. These 261 
observations indicate ‘adaptive tuning’ of residual undeleted insulin-specific CD8
+
Tmem to the 262 
proinsulin expressed in PI-Tg recipients.  An unexpected finding was that CD5, which is an 263 
indicator of antigen-sensing 
39
 and upregulated by tolerant T cells in many settings 
26, 40
 was not 264 
upregulated by inactivated G9 Tmem in PI-Tg recipients. This could perhaps reflect altered 265 
regulation of CD5 in Tmem, particularly as CD5 expression was reduced during in vitro Tm 266 
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differentiation (Suppl. 2).  Alternatively downstream signalling may be blocked proximally to 267 
the TCR 
41
 thereby preventing CD5 upregulation.   268 
 269 
Here, enforced proinsulin expression was controlled by an MHC class II promoter, targeting 270 
proinsulin expression to DC, B cells and possibly other APC.  In other studies, targeting 271 
expression of a model antigen using an MHC class II promoter also led to rapid deletion and 272 
TCR down-regulation, and loss of effector function but in high-affinity ovalbumin (OVA)-273 
specific memory CD8
+
 T cells 
18
.  Rapid deletion and TCR down-regulation appears to be the 274 
consequence of extensive antigen expression in such settings 
18, 29
 and perhaps this is mediated 275 
by inclusion of B cells as antigen-expressing APC 
42, 43
.  Whether ‘high dose’ antigen is critical 276 
for effective inactivation of insulin-specific CD8
+
 memory T cells is yet to be fully explored, but 277 
inactivation of insulin-specific CD8
+
 memory T cells proceeded even when low proportions of 278 
APC expressed proinsulin as this was similar to studies using OVA 
18
 suggesting the altered 279 
immunoregulatory environment of NOD mice has little influence on this.  One key component of 280 
tolerance induction by enforced antigen expression is persistent exposure to antigen 
44
, making 281 
gene therapy approaches that achieve long-term antigen expression highly applicable. Certainly, 282 
transfer of genetically-modified hematopoietic stem cells shows gene therapy has the potential to 283 
be an effective treatment 
26, 44, 45
 and this is capable of preventing recurrent autoimmune attack of 284 
transplanted islets 
26
. Here we found no inflammatory infiltrates in pancreatic islets of PI-Tg 285 
recipients of G9 Tmem, even after immunization (e.g. Fig. 4) or CTL (e.g. Fig. 6) suggesting 286 
that a component of protection may be mediated through limiting T-cell traffic to target tissues 287 
as described previously 
18
.   Importantly, the mechanisms that we find underlie tolerance 288 
induction by enforced antigen expression and HSC-mediated gene therapy appear to replicate 289 
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those found in some clinical studies 
46
 emphasizing the potential clinical applicability of this 290 
approach. Interestingly, plasmid vaccines show promise as a gene-therapy approach and this has 291 
been exploited by a proinsulin encoding DNA vaccine that displays a degree of efficacy 
47
 even 292 
though expression of encoded antigen is likely transient. Whether transient expression of antigen 293 
carries a risk of boosting rather than inhibiting memory responses remains unclear, as does the 294 
minimum period of ‘antigen exposure’ required to induce Tmem inactivation.  However, 295 
approaches exploiting enforced antigen expression for tolerance induction, under some 296 
circumstances, may not need to induce long-term antigen expression if a physiological source of 297 
antigen is present to ‘maintain’ tolerance 
48
. Such approaches may be ideally suited for early 298 
stages of T1D where endogenous islet antigens present in residual islets can ‘maintain’ tolerance, 299 
once established.  300 
 301 
It is worthy of consideration that PI-Tg mice are normally devoid of islet inflammation 
25, 45
 and 302 
this could influence the process of tolerance induction in transferred insulin-specific CD8
+
 T 303 
cells. In the absence of islet inflammation, trafficking of G9 Tmem or CTL to pLN or pancreatic 304 
islets may be reduced, perhaps contributing to reduced pathogenicity. Other than an initial 305 
accumulation in spleen, G9 Tm are equally infrequent in the tissues examined in  PI-Tg 306 
recipients although there may be a propensity for G9 Tmem to accumulate in pLN (Fig. 1, 307 
Suppl. 3), and possibly pancreatic islets, in non-Tg NOD recipients.  Activated/effector islet-308 
antigen specific CD4
+
 T cells might act to limit CD8+ T-cell tolerance 
49
 in non-Tg NOD mice 309 
and the absence of these cells in PI-Tg mice facilitate the ready induction of tolerance in G9 310 
Tmem by proinsulin-expressing APC.  It would be interesting to determine the effect of co-311 
transferred activated islet-antigen specific CD4
+
 T cells, or even other specificities of islet-312 
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antigen specific CD8
+
 T cells, on tolerance induction to understand the influence of ‘help’ on 313 
tolerance induction and to understand the potential for tolerance induction in an ‘inflamed’ 314 
setting.  Interestingly, we have recently that memory/effector Th2-skewed CD4+ T cells are 315 
readily inactivated by enforced antigen expression in APC 
50
  and this could potentially extend to 316 
diabetogenic CD4
+
 T cells.  317 
  318 
A key challenge for therapy of T1D is that epitope and determinant spreading occurs as diseases 319 
develops, necessitating the development of immunotherapeutic approaches that are able to 320 
control the diverse anti-islet effector, and ultimately, memory T cell specificities that emerge 321 
during disease development.  As T cell responses to (pro)insulin play such an important role 322 
early in disease development, our findings indicate that approaches where proinsulin is 323 
overexpressed early during disease development may hold great therapeutic promise.  324 
17 
 
METHODS 325 
Mice 326 
Transgenic mice (PI-Tg) expressing mouse proinsulin II under an MHC class II (I-Eαk) promoter 327 
have been described 
25
. G9C8 (G9) mice carry insulin B15-23-specific TCR transgenic (Vα18, 328 
Vȕ6) T cells 24 and NOD.CD45.2 mice carry a congenic CD45 allele 51.  B16 mice lack both 329 
insulin 1 and insulin 2 (PI1
-/-
 PI2
-/-
) and express a mutated preproinsulin (B16A) under a rat 330 
insulin promoter 
52
. Non-transgenic NOD/ShiLtJArc (CD45.1
+
) mice were purchased from the 331 
Animal Resources Facility (Perth, WA). Non-Tg and PI-Tg mice were crossed to NOD.CD45.2 332 
mice to obtain (CD45.1
+
/CD45.2
+
) F1 offspring. All mice were bred and/or housed under 333 
specific pathogen-free conditions in the Princess Alexandra Hospital Biological Resources 334 
Facility (Brisbane, Australia), the Translational Research Institute Biological Resources Facility 335 
(Brisbane, Australia).  Male mice 8-12 weeks of age randomly assigned to boxes were used for 336 
all experiments except analysis of diabetes onset after transfer of G9 CTL where 11-12 week-old 337 
female mice were used. All animal experiments were approved by The University of Queensland 338 
Animal Ethics Committee (Projects 164/12, 144/15). 339 
 340 
Adoptive transfers and in vivo assays 341 
For in vitro-generated G9 Tmem, LN (axillary, brachial, inguinal, mesenteric) cells were 342 
cultured in the presence of insB15-23 (10µg/ml; Auspep, Australia) and rhIL-2 (10ng/ml; 343 
PeproTech, Australia) in complete RPMI/5% HI-FCS for 3 days, washed and recultured with IL-344 
15 (10ng/ml; PeproTech, Australia) for an additional 2 days as described 
17
. To generate CTL, 345 
G9 LN cells were cultured in the presence of insB15-23 (10µg/ml; Auspep, Australia) and rhIL-2 346 
(10ng/ml; PeproTech, Australia) for 2 days.  Cultured cells (>90% G9 T cells) were washed prior 347 
18 
 
to i.v. injection (lateral tail vein, 2 x 10
6
 unless specified otherwise). Labelling with 348 
carboxyfluorescein diacetate succinimidyl ester (CFSE) was as described previously 
53
. To test 349 
antigen-responsiveness some mice were immunised i.p. with insB15-23/IFA/poly IC 350 
(50µg/100µg).  Mice were screened for glycosuria weekly using Diastix Reagent Strips (Bayer, 351 
Leverkusen, Germany). Blood glucose was then determined for glycosuric mice using an Accu-352 
Chek Go glucometer (Roche, Basel, Switzerland) and mice were deemed diabetic following two 353 
consecutive blood glucose readings >12mM.  To generate mixed bone marrow (BM) chimeras, 354 
graded mixtures of  PI-Tg (CD45.1
+
CD45.2
+
) and non-Tg (CD45.2
+
) BM were transferred to 355 
lethally irradiated NOD.CD45.2 recipients using procedures described elsewhere 
18
. 356 
 357 
Flow cytometry and in vitro assays 358 
At indicated timepoints, recipient spleens, skin-draining LN (sdLN; pooled inguinal, axilliary, 359 
brachial) and pancreatic LN (pLN) were harvested, disrupted by pressing through cell strainers 360 
(BD Falcon) and erythrocytes lysed with hypotonic NH4Cl/Tris buffer (spleens only).  Cells were 361 
washed, and prepared for further analysis. Fluorochrome-conjugated antibodies were purchased 362 
from BioLegend (San Diego, CA, USA), eBioscience (San Diego, CA, USA) or produced and 363 
conjugated in-house (listed in Suppl. 4). PE-conjugated tetramers loaded with the insB15-23 364 
(LYLVCGERV) APL that exhibits high affinity for H2-K
d
 
54
 (K
d
-insB15-23) or listeriolysin 365 
(LLO)91-99 (GYKDGNEYI) were sourced from the NIH Tetramer Facility.  G9 T cells were 366 
typically defined as CD45.1
+
CD45.2
-
CD8
+
Vȕ6+ cells although when B16 recipients were used, 367 
G9 were defined as CFSE
+
CD8
+
Vȕ6+ in these mice. Data were collected using FACSCanto, 368 
LSRII (BD Biosciences) or Gallios (Beckman Coulter) cytometers and analyzed with FACSDiva 369 
(BD Biosciences), Kaluza (Beckman Coulter) or FlowJo (TreeStar Inc) software.  To enumerate 370 
19 
 
cell number, cytometric bead-based counting assays were performed as described 
51
. 371 
Proliferation index for CFSE dilution assays was calculated as described 
55
. ELISpots were 372 
performed as described previously 
53
 using insB15-23 at 10µg/ml.  Data are displayed as Δ spot 373 
forming cells (Δ SFC = # spots with stimulation - # spots in no stimulation control). 374 
 375 
Statistical Analysis 376 
Pairwise comparison of means was performed with appropriate use of a two-tailed Student’s t-377 
test and multiple groups with a one-way ANOVA followed by Tukey post-test (GraphPad 378 
Prism).  Analyses of diabetes development following G9 CTL transfer were performed by Log-379 
rank (Mantel Cox) test (GraphPad Prism).  Exact sample numbers/group and sampling procedure 380 
is listed in each Figure legend.  No blinding of groups was performed.  Sample sizes were based 381 
on prior experience with these models and the minimum number of animals were used to obtain 382 
statistically significant differences where these existed. 383 
  384 
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Figure Legends  606 
Figure 1.  G9 Tmem are deleted in PI-Tg recipients 607 
A,B)  CFSE-labelled G9 Tmem were transferred to B16A, non-Tg or PI-Tg recipients and three 608 
days later spleen, skin-draining LN (sdLN) and pancreatic LN (pLN) harvested and dye dilution 609 
determined using flow cytometry. Representative histograms show the extent of division, 610 
proportion divided (mean ± SD) (A) and proliferation index (B). C)  G9 T cells were transferred 611 
to congenically-distinct (CD45.1
+
/CD45.2
+
) NOD or PI-Tg recipients and G9 T cells 612 
(CD45.1
+
/CD45.2
-
CD8
+
/Vȕ6+ ) enumerated as indicated.  Data (A,B) are pooled from 2 613 
independent experiments and cytometry plots (B) are representative of 4-6 individual mice or for 614 
(C) data are pooled from at least two independent experiments per timepoint (day 1 n=5, day 2 615 
n=6, day 3 n=5, day 5 n=6, day 7 n=11). Plots show individual mice and mean ± SD (B) or mean 616 
± SD (C).  ANOVA with Tukey’s post-test. 617 
 618 
Figure 2.  G9 Tmem TCR expression is reduced in PI-Tg recipients.  619 
A,B) G9 Tmem were transferred to NOD or PI-Tg recipients and seven days later (A) or at the 620 
indicated times (B) TCR Vȕ6 expression was determined by flow cytometry and plotted relative 621 
to that of host CD8
+
 Vȕ6 T cells. C) Mixed chimeras were generated and 6 weeks later G9 622 
Tmem transferred. Three days later mice were analysed for engraftment proportions and Vȕ6 623 
TCR expression. Data are representative FACS plots (A), mean ± SD ((day 1 n=5, day 2 n=6, 624 
day 3 n=5, day 5 n=6, day 7 n=11) pooled from 2-3 experiments per time point (B) or individual 625 
values pooled from 2 experiments showing 4 parameter non-linear curve fit (C). ANOVA with 626 
Tukey’s post-test was used to compare means (B).    627 
 628 
Figure 3.  Tetramer binding by G9 Tmem is reduced in PI-Tg recipients.  629 
A-E) G9 Tmem cells were transferred to non-Tg or PI-Tg recipients and three days later G9 T 630 
cell (CD45.1
+
/CD45.2
-
CD8
+
/Vȕ6+) Kd-insB15-23 tetramer binding and Vȕ6 expression were 631 
determined by flow cytometry.  Depicted is K
d
-insB15-23-binding by G9 T cells (solid lines) or 632 
host PI-Tg CD8
+
 Vȕ6+ T cells where the vertical dotted line denotes the cut-off used to define 633 
K
d
-insB15-23
hi
 T cells (A). The proportion of G9 T cells binding high levels of K
d
-insB15-23 G9 634 
cells was calculated (B). Vȕ6 expression on G9 relative to host CD8+ and Kd-insB15-23-binding 635 
normalised to the mean value for  non-Tg recipients in each experiment was plotted (C).  Total 636 
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number of K
d
-insB15-23
hi
 G9 T cells (D) or their proportion of total CD8
+
 T cells was calculated. 637 
Data are representative FACS plots (A), data points for individual organs from individual mice 638 
(D) or individual mice with mean ± SD pooled from 2 or more experiments (B,D,E). ANOVA 639 
with Tukey’s post-test or Student’s t-test (D,E). 640 
 641 
Figure 4  G9 Tmem are rendered unresponsive in PI-Tg recipients 642 
 (A,B) G9 Tmem were transferred to congenically-distinct (CD45.1
+
/CD45.2
+
) non-Tg or PI-Tg 643 
recipients that were five days later immunised or not with insB15-23/IFA/poly I:C. A further 5 644 
days later G9 T cells (CD45.1
+
/CD45.2
-
/CD8
+
/Vȕ6+) were enumerated in spleen using flow 645 
cytometry (A) and insB15-23-responsive IFN-Ȗ-producing cells determined by ELISpot (B). Data 646 
are pooled from 2 experiments and show individual mice and mean ± SD. ANOVA with Tukey’s 647 
post-test.  648 
 649 
Figure 5.  G9 Tmem express elevated levels of co-inhibitory molecules in PI-Tg recipients  650 
A-K) G9 Tmem were transferred to congenically-distinct (CD45.1
+
/CD45.2
+
) non-Tg or PI-Tg 651 
recipients and 5 days later G9 T cells (CD45.1
+
/CD45.2
-
/CD8
+
/Vȕ6+) were analysed by flow 652 
cytometry.  Data points show individual mice pooled from 2 experiments with mean ± SD. 653 
ANOVA with Tukey’s post-test. 654 
 655 
Figure 6.  Transgenic proinsulin expression inhibits insulin-specific CTL effector function 656 
A)  G9 LN and spleen cells were cultured with B15-23 and IL-2 for 2 days and transferred i.v. to 657 
11-12 week-old female non-Tg or PI-Tg recipients and diabetes onset compared to 658 
contemporaneous untransferred controls. Urinary glucose was monitored twice-weekly and 659 
diabetes onset confirmed when 2 consecutive blood glucose were > 12mM.  Mantel Cox log-660 
rank test #: p=0.0078,  †: p=0.0371.   B,C)  G9 LN and spleen cells were cultured with B15-23 and 661 
IL-2 for 2 days and transferred i.v. to 9 week-old female non-Tg (NOD.CD45.2) or PI-Tg (PI-Tg 662 
x NOD.CD45.2) mice.  Three days later tissues were harvested and G9 (CD45.1
+
/CD45.2
-
663 
/CD8
+
/Vȕ6+) T cells analysed by flow cytometry.  Data points show individual mice pooled from 664 
2 experiments with mean ± SD. t-test was used to compare means. 665 






